Icon: enlarge
Johnson & Johnson is also developing a vaccine against Sars-Cov-2
Photo: Michael Ciaglo / AFP
The EU apparently expects the vaccine manufacturer Johnson & Johnson to apply for approval for its Covid vaccine in February.
The EU Health Commissioner Stella Kyriakides said on Wednesday in a meeting with the conservative EPP group in the EU Parliament, said the CDU MP Peter Liese.
Johnson & Johnson has developed what is known as a vector vaccine.
This contains an adenovirus that is harmless to humans and is unable to multiply.
The genetic information for the Sars-CoV-2 spike protein was built into this virus.
The technique has already been used for a vaccine against Ebola.
The EU has secured 200 million doses of the vaccine plus an option for an additional 200 million doses.
Johnson & Johnson is testing the vaccine in two large Phase III trials - both a single dose and two doses of the vaccine.
In mid-December, the company announced that it expected data from the first Phase III study for the end of January.
“If that works, then we have the fourth corona vaccine.
The Johnson & Johnson vaccine has the advantage that with this vaccine you only need one vaccination to be adequately protected and it is much easier to process, store and transport than the Biontech / Pfizer vaccine, ”said Liese.
The corona vaccines from Biontech / Pfizer and Moderna are already approved.
In addition, on January 12th, AstraZeneca applied for approval of its product in the EU.
The European Medicines Agency Ema announced that a decision could be made as early as the end of January.
Icon: The mirror
wbr
